BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123

Title:

BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123

Document Type and Number:

Japanese Patent JP2022105138

Kind Code:

A

Abstract:

To provide antibody-like binding protein specifically binding to CD3 and CD123, pharmaceutical compositions comprising the antibody-like binding protein, and the use of the pharmaceutical compositions and the antibody-like binding protein to treat cancer.SOLUTION: An antibody-like binding protein binds specifically to human CD3ε and human CD123, comprising two polypeptide chains that form two antigen-binding sites, wherein a polypeptide chain having a specific sequence includes Fc and forms a cross over light chain-heavy chain pair.SELECTED DRAWING: None

Inventors:

JANA ALBRECHT
CHIRSTIAN BIEL
JOCHEN BENINGA
KATJA KROLL
CHRISTIAN LANGE
WULF DIRK LEUSCHNER
ERCOLE RAO
MARION SCHNEIDER
PETER WONEROW
STEPHANE GUERIF

Application Number:

JP2022075664A

Publication Date:

July 12, 2022

Filing Date:

May 02, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

SANOFI SA

International Classes:

C12N15/13; A61K39/395; A61P35/00; A61P35/02; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10

Domestic Patent References:

JP7071329B2

2022-05-18

Attorney, Agent or Firm:

Junji Yuda
Noriyuki Takebayashi

Previous Patent: Stabilized pharmaceutical formulations of insulin analogs and / or insulin derivatives

Next Patent: Methods and Compositions for Reducing the Immunogenicity of Chimeric NOTCH Receptors